AU2020368556B2 - Lipid and lipid nanoparticle formulation for drug delivery - Google Patents
Lipid and lipid nanoparticle formulation for drug deliveryInfo
- Publication number
- AU2020368556B2 AU2020368556B2 AU2020368556A AU2020368556A AU2020368556B2 AU 2020368556 B2 AU2020368556 B2 AU 2020368556B2 AU 2020368556 A AU2020368556 A AU 2020368556A AU 2020368556 A AU2020368556 A AU 2020368556A AU 2020368556 B2 AU2020368556 B2 AU 2020368556B2
- Authority
- AU
- Australia
- Prior art keywords
- lnp
- antigen
- lipid
- mol
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Dispersion Chemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962923258P | 2019-10-18 | 2019-10-18 | |
| US62/923,258 | 2019-10-18 | ||
| PCT/US2020/056252 WO2021077066A1 (en) | 2019-10-18 | 2020-10-19 | Lipid and lipid nanoparticle formulation for drug delivery |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2026213955A Division AU2026213955A1 (en) | 2019-10-18 | 2026-08-04 | Lipid and lipid nanoparticle formulation for drug delivery |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2020368556A1 AU2020368556A1 (en) | 2022-05-19 |
| AU2020368556B2 true AU2020368556B2 (en) | 2026-05-07 |
Family
ID=75538682
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020368556A Active AU2020368556B2 (en) | 2019-10-18 | 2020-10-19 | Lipid and lipid nanoparticle formulation for drug delivery |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220396556A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4045020A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2022552009A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220084365A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114828836A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020368556B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3155074A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021077066A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117098541A (zh) | 2020-11-25 | 2023-11-21 | 阿卡格拉医药公司 | 用于递送核酸的脂质纳米粒及相关使用方法 |
| CN113785975B (zh) * | 2021-09-09 | 2023-08-29 | 天津医科大学 | 精胺、亚精胺脂质体在抗氧化、抗衰老中的应用 |
| AR128959A1 (es) * | 2022-04-04 | 2024-06-26 | Spark Therapeutics Inc | Mejora inmunológica del tratamiento del cáncer |
| WO2023196527A2 (en) * | 2022-04-08 | 2023-10-12 | SunVax mRNA Therapeutics Inc. | Ionizable lipid compounds and lipid nanoparticle compositions |
| WO2023230587A2 (en) | 2022-05-25 | 2023-11-30 | Akagera Medicines, Inc. | Lipid nanoparticles for delivery of nucleic acids and methods of use thereof |
| WO2024061354A1 (zh) * | 2022-09-23 | 2024-03-28 | 北京键凯科技股份有限公司 | 一种抑制top1基因表达的干扰rna及其应用 |
| CN118946544A (zh) * | 2023-03-09 | 2024-11-12 | 上海吉量医药工程有限公司 | 可离子化脂质分子及其制备方法和应用 |
| CN116082184B (zh) * | 2023-04-12 | 2023-06-30 | 山东大学 | 基于环己二胺的可电离脂质、脂质纳米颗粒及其制备方法与应用 |
| WO2025038494A1 (en) | 2023-08-11 | 2025-02-20 | Tune Therapeutics, Inc. | Compositions, systems, and methods for lymphoid cell differentiation using targeted gene activation |
| EP4777496A1 (en) * | 2023-09-11 | 2026-07-22 | The Trustees of The University of Pennsylvania | Compositions and methods for t cell targeted extrahepatic delivery of therapeutic agents |
| CN117482066B (zh) * | 2023-11-02 | 2024-08-13 | 深圳市易瑞生物技术股份有限公司 | 脂质组合物和用于脂质组合物的化合物 |
| WO2025209467A1 (en) * | 2024-04-01 | 2025-10-09 | Longuide Biopharma Corporation | Lipids and lipid nanoparticle formulations |
| WO2026003582A2 (en) | 2024-06-27 | 2026-01-02 | Axelyf ehf. | Lipids and lipid nanoparticles |
| WO2026161895A1 (en) | 2025-01-27 | 2026-07-30 | Tune Therapeutics, Inc. | Compositions, systems, and methods for epigenetic regulation of lipoprotein a (lpa) gene expression |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010053572A2 (en) * | 2008-11-07 | 2010-05-14 | Massachusetts Institute Of Technology | Aminoalcohol lipidoids and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009303345B2 (en) * | 2008-10-09 | 2015-08-20 | Arbutus Biopharma Corporation | Improved amino lipids and methods for the delivery of nucleic acids |
| US7635707B1 (en) * | 2008-11-10 | 2009-12-22 | Intermune, Inc. | Pirfenidone treatment for patients with atypical liver function |
| WO2015011633A1 (en) * | 2013-07-23 | 2015-01-29 | Protiva Biotherapeutics, Inc. | Compositions and methods for delivering messenger rna |
| WO2018081638A1 (en) * | 2016-10-27 | 2018-05-03 | The Trustees Of The University Of Pennsylvania | Nucleoside-modified rna for inducing an adaptive immune response |
-
2020
- 2020-10-19 CA CA3155074A patent/CA3155074A1/en active Pending
- 2020-10-19 EP EP20877084.2A patent/EP4045020A4/en active Pending
- 2020-10-19 US US17/769,858 patent/US20220396556A1/en active Pending
- 2020-10-19 KR KR1020227016630A patent/KR20220084365A/ko not_active Ceased
- 2020-10-19 JP JP2022523031A patent/JP2022552009A/ja active Pending
- 2020-10-19 WO PCT/US2020/056252 patent/WO2021077066A1/en not_active Ceased
- 2020-10-19 AU AU2020368556A patent/AU2020368556B2/en active Active
- 2020-10-19 CN CN202080088019.XA patent/CN114828836A/zh active Pending
-
2025
- 2025-11-04 JP JP2025185622A patent/JP2026012402A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010053572A2 (en) * | 2008-11-07 | 2010-05-14 | Massachusetts Institute Of Technology | Aminoalcohol lipidoids and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| US20220396556A1 (en) | 2022-12-15 |
| KR20220084365A (ko) | 2022-06-21 |
| CN114828836A (zh) | 2022-07-29 |
| JP2026012402A (ja) | 2026-01-23 |
| JP2022552009A (ja) | 2022-12-14 |
| WO2021077066A1 (en) | 2021-04-22 |
| EP4045020A1 (en) | 2022-08-24 |
| CA3155074A1 (en) | 2021-04-22 |
| AU2020368556A1 (en) | 2022-05-19 |
| EP4045020A4 (en) | 2024-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220378700A1 (en) | Lipid Nanoparticles and Formulations Thereof for CAR mRNA Delivery | |
| US20220396556A1 (en) | Lipid and Lipid Nanoparticle Formulation for Drug Delivery | |
| US12138305B2 (en) | Nucleoside-modified RNA for inducing an adaptive immune response | |
| US20190274968A1 (en) | Nucleoside-modified rna for inducing an adaptive immune response | |
| US20210170017A1 (en) | Novel rsv rna molecules and compositions for vaccination | |
| US20240408031A1 (en) | Compositions and methods for t cell targeted delivery of therapeutic agents | |
| AU2022354266A1 (en) | Lipid nanoparticle (lnp) compositions and methods of use thereof | |
| CN118695850A (zh) | 通用流感疫苗及使用方法 | |
| WO2026085452A1 (en) | Optimized formulation of ionizable amphiphilic janus dendrimer delivery systems, and methods of use thereof | |
| WO2026085256A1 (en) | Lipid nanoparticles and methods of use | |
| WO2025111442A1 (en) | Lipid nanoparticles and methods of use for dna delivery | |
| WO2025059112A1 (en) | Compositions and methods for t cell targeted extrahepatic delivery of therapeutic agents | |
| WO2025038627A2 (en) | Pentaerythritol-based ionizable amphiphilic janus dendrimers, delivery systems comprising thereof, and methods of use thereof | |
| EA052995B1 (ru) | Композиции липидных наночастиц (lnp) и способы их применения |